1. Hudson
Health Sciences Raises $4,700,000 in Financing [South San Francisco,
CA]
Hudson Health Sciences is a biopharmaceutical company focused
on acquiring, developing and commercializing innovative products
for the treatment of important unmet medical needs, including
cancer and immunological diseases.
INVESTORS: Undisclosed (Lead)
2/26/2004 12:03:14 PM
2. Diatos
Raises $8,880,000 in New Round [France]
Diatos is a developer of drug delivery solutions used in the treatment
of cancer and infectious diseases.
INVESTORS: Innoven Partners (Lead), Credit Lyonnais Private
Equity, GIMV, NIF Ventures
2/25/2004 11:50:36 AM
3. Aegera
Therapeutics Raises $15,000,000 in Third Round [Canada]
Aegera Therapeutics is a private North American biotechnology
company focused on exploiting apoptosis control to extend and
enhance the lives of cancer patients: killing cancer cells by
inducing apoptosis and rescuing neurons from apoptotic cell death.
INVESTORS: VenGrowth Capital (Lead), Business Development
Bank of Canada (BDC), Desjardins Venture Capital, Fondaction,
GeneChem Management, GrowthWorks Capital, Innovatech Grand Montreal,
Solidarity Fund QFL
2/24/2004 4:14:00 PM
4. Domantis
Raises $33,000,000 in Series B Round [Cambridge, MA]
Domantis is a developer of drugs with a focus on the smallest
antibody fragments called Domain Antibodies(dAbs).
INVESTORS: 3i Group (Lead), Albany Ventures, Gray Ghost,
MVM Limited
2/24/2004 12:27:25 PM
5. AlgoRx
Pharmaceuticals Raises $65,000,000 in Series C Round [Cranbury,
NJ]
AlgoRx Pharmaceuticals is a developer of pharmaceutical products
and technologies to address the large unsatisfied pain market.
INVESTORS: Advent International (Lead), Axiom Venture Partners,
Cogene Biotech Ventures, EGS Healthcare Capital Partners, Hunt
Ventures, Index Ventures, InterWest Partners, JPMorgan Partners,
Lehman Brothers Venture Partners, NIF Ventures, Pacific Rim Ventures,
P...
2/24/2004 12:07:15 PM
6. NeurogesX
Raises $35,000,000 in Series C Round [San Carlos, CA]
NeurogesX is a developer of therapeutic agents for the treatment
of nerve signaling disorders that result in a variety of disabling
conditions including pain.
INVESTORS: Global Life Science Ventures (Lead), Alta Partners,
ARCH Venture Partners, Diamond Capital, Montreux Equity Partners,
TIAA-CREF, University of North Carolina Endowment Fund, Walden
International
2/24/2004 11:33:00 AM
7. Chaperone
Technologies Raises Seed Financing Round [Wayne, PA]
Chaperone Tecnologies is a developer of antimicrobial products,
based on a novel and proprietary mechanism of action, for difficult-to-treat
and drug-resistant organisms across a broad range of infectious
diseases.
INVESTORS: Innovation Philadelphia
2/23/2004 3:37:04 PM
8. Y's
Therapeutics Raises $22,000,000 in Series B Round [Japan]
Y's Therapeutics is a privately held drug development biotechnology
company developing truly effective next-generation drugs with
a focus on antibody therapeutics and small molecule products for
cancer, autoimmune diseases and inflammatory diseases.
INVESTORS: SOFTBANK CORP. (Lead), BioVision
2/23/2004 10:17:46 AM
9. Acceleron
Pharma Raises $25,000,000 in Series A Round [Cambridge, MA]
Acceleron is a biopharmaceutical company developing drugs for
important unmet medical needs through proprietary approaches that
exploit the therapeutic potential of a large family of growth
and differentiation factors.
INVESTORS: Polaris Venture Partners (Lead), Advanced Technology
Ventures, Flagship Ventures, Sutter Hill Ventures, Venrock Associates
2/13/2004 2:31:42 PM
10. Kadmus
Pharmaceuticals Raises $15,300,000 in Series A Round
Kadmus Pharmaceuticals is a developer of proprietary molecules
that target critical pathways contributing to pain and other disorders
of the nervous system.
INVESTORS: VenGrowth Capital (Lead), CDP Capital, Gray
Ghost, Sanderling Ventures, Singapore Economic Development Board,
Softbank Capital Partners
2/9/2004 12:34:43 PM
11. Accentia
Raises $5,000,000 in Corporate Round [Tampa, FL]
Accentia is a vertically-integrated specialty biopharmaceutical
company, formed by the Hopkins Capital Group and affiliates to
acquire late-stage targeted therapeutics and to use patented delivery
technologies to enhance the performance of these therap...
INVESTORS: PPD
2/4/2004 8:45:51 AM
12. XenoPort
Raises $39,960,000 in Series C Recap Round [Santa Clara, CA]
XenoPort is a biopharmaceutical company focused on developing
products which harness the body's intrinsic transport systems
to improve the oral absorption, distribution, and pharmacokinetics
of drugs. The company applies an integrated technology platfo...
INVESTORS: ARCH Venture Partners, Frazier Healthcare Ventures,
Skyline Ventures, Venrock Associates
2/3/2004 5:29:22 PM
13. Hyalozyme
Therapeutics Raises $9,200,000 [San Diego, CA]
Hyalozyme Therapeutics is a specialty pharmaceutical company focused
on the development and commercialization of recombinant therapeutic
enzymes and drug enhancement systems based on intellectual property
covering the family of human enzymes known as h...
INVESTORS: Grove Capital (Lead), Cimarron Biomedical Investors,
Colt Ventures, Others
2/3/2004 12:00:54 PM
14. Icagen
Raises $19,500,000 [Durham, NC]
Icagen is a pharmaceutical discovery and development company,
focusing exclusively on ion channels as drug targets. The company
has developed an integrated technology platform able to rapidly
discover small molecule therapeutics for a broad spectrum of...
INVESTORS: Alta Partners, China Development Industrial
Bank, HBM Partners (HBM BioVentures), J.P. Morgan Partners, Quintiles
Transnational, Venrock Associates
2/2/2004 12:59:24 PM
15. ExonHit
Therapeutics Raises $10,300,000 [France]
ExonHit Therapeutics is a drug discovery company for cancer and
neurodegenerative diseases through the analysis of splicing events.
The company's qualitative gene profiling technology, DATAS, has
enabled the development of therapeutic and diagnostic pr...
INVESTORS: Undisclosed
2/2/2004 12:15:27 PM
16. SelectX
Pharmaceuticals Raises Up to $8,000,000 in Series B Round [Worcester,
MA]
SelectX Pharmaceuticals is a provider of bio-medicinal drug discovery
and a developer of natural product-like compounds. The company
is defining a new paradigm for drug discovery based on molecular
selection as opposed to screening, offering significan...
INVESTORS: BU Community Technology Fund, Inventages Ventures
Capital (Nestle), Techno Venture Management (TVM)
1/23/2004 10:40:06 AM
17. Cellular
Genomics Raises $22,300,000 in Series C Round [Branford, CT]
Cellular Genomics is a genomics-based biopharmaceutical company
pioneering a highly integrated chemical genetics platform for
drug discovery and development. The company has established small
molecule drug discovery programs focused on discovering and ...
INVESTORS: Lilly Ventures (Lead), Coastview Capital, Connecticut
Innovations, Emerging Technology Partners, Flagship Ventures,
MPM Capital, Vector Fund Management
1/21/2004 9:51:47 AM
18. Phytomedics
Raises $7,500,000 in Series A Round [Dayton, NJ]
Phytomedics is a developer of novel, multi-component, and multi-functional
botanical therapeutics such as botanical drugs and nutraceuticals,
as well as recombinant proteins. The company has produced a pipeline
of pharmaceutical and nutraceutical lead ...
INVESTORS: Inventages Ventures Capital (Nestle) (Lead),
Burrill & Company
1/20/2004 12:22:05 PM
19. Peninsula
Pharmaceuticals Raises $57,900,000 in Series C Round [Alameda,
CA]
Peninsula Pharmaceuticals is a developer of optimal anti-infective
therapies for the treatment of patients with life-threatening
infections.
INVESTORS: A.M. Pappas & Associates, Canaan Partners,
Domain Associates, Montreux Equity Partners
1/16/2004 1:09:03 PM
20. TargeGen
Raises $30,000,000 in Second Round [San Diego, CA]
TargeGen is a developer of novel therapeutics to treat cancer
and ischemic disease (stroke, heart attack) by regulating the
processes associated with new blood vessel formation (angiogenesis)
and vascular permeability.
INVESTORS: CDP Capital-Technology Ventures (CDP Sofinov),
China Development Industrial Bank, Enterprise Partners, Forward
Ventures, William Blair Capital Partners
1/14/2004 4:47:56 PM
21. Enanta
Pharmaceuticals Raises $12,000,000 in Financing [Watertown, MA]
Enanta Pharmaceuticals is a developer of small-molecule drugs
by using chemistry technology and transforming existing drugs,
natural products, and biologically active peptides.
INVESTORS: Advent International, BioVentures Investors,
NIB Capital Private Equity, Oxford Bioscience Partners, Swiss
Life Private Equity Partners, Techno Venture Management, Yasuda
Enterprise Development
1/14/2004 3:32:07 PM
22. Synta
Pharmaceuticals Raises $50,000,000 in Financing [Lexington, MA]
Synta Pharmaceuticals is an emerging pharmaceutical company focused
on discovering, developing, and commercializing breakthrough products
for severe medical conditions.
INVESTORS: AIG SunAmerica
1/14/2004 1:54:37 PM
23. Vascular
Biogenics Raises $5,000,000 in Financing [Israel]
Vascular Biogenics is a developer of drug treatments for vascular
conditions.
INVESTORS: Teva Pharmaceuticals (Lead)
1/13/2004 9:49:36 AM
24. OyaGen
Raises Seed Financing Round [Rochester, NY]
OyaGen is a developer of a class of HIV drugs that may enable
the body's own immune system to halt an HIV infection.
INVESTORS: Trillium Group (Lead)
1/12/2004 4:39:37 PM
25. Metabolex
Raises $4,000,000 in Sixth Round Add-on [Hayward, CA]
Metabolex is a developer of therapeutics for type 2 diabetes.
INVESTORS: Birchmere Ventures, CIBC World Markets, Merlin
Biosciences
1/12/2004 12:19:34 PM
26. Hydra
Biosciences Raises $18,875,000 in Series B Round [Cambridge, MA]
Hydra Biosciences is a developer of molecular regeneration medicines,
cardiovascular therapies and drugs targeting ion channels.
INVESTORS: Lilly Bioventures (Lead), Abbott Laboratories,
Abingworth Management, Advanced Technology Ventures, BioVentures
Investors, Boston Medical Technologies, New Enterprise Associates
(NEA), Polaris Venture Partners
1/12/2004 12:08:23 PM
27. Concurrent
Pharmaceuticals Raises $15,000,000 in Series B Round [Fort Washington,
PA]
Concurrent Pharmaceuticals is a developer of an integrated technology
platform that will enable the de-novo design of bioactive molecules
"in silico."
INVESTORS: Intel Capital, New Enterprise Associates (NEA),
Prospect Venture Partners, Venrock Associates
1/12/2004 11:08:49 AM
28. Threshold
Pharmaceuticals Raises $41,000,000 in Series B Round [South San
Francisco, CA]
Threshold Pharmaceuticals is a developer of novel therapeutics
to target metabolic pathways for application in the field of oncology.
INVESTORS: Morgenthaler Ventures (Lead), CHL Medical Partners,
Pequot Ventures, ProQuest Investments, Sofinnova Ventures, Sutter
Hill Ventures, Three Arch Partners
1/12/2004 10:39:42 AM
29. Inhibitex
Raises $18,250,000 in Series E Round [Alpharetta, GA]
Inhibitex is a clinical stage, biopharmaceutical company focused
on developing and commercializing a pipeline of novel "first-in-field"
antibody-based products to prevent and treat serious bacterial
and fungal infections.
INVESTORS: Undisclosed
1/9/2004 11:20:30 AM
30. Auxeris
Therapeutics Raises $1,600,000 in Series A Round Add-on [Saint
Louis, MO]
Auxeris Therapeutics is a biopharmaceutical company focused on
the development and commercialization of medicines to treat a
broad range of bone diseases.
INVESTORS: Domain Associates, RiverVest Venture Partners
1/9/2004 10:44:26 AM
31. Infinity
Pharmaceuticals Raises $25,000,000 in Corporate Round [Cambridge,
MA]
Infinity Pharmaceuticals is a drug discovery company developing
approaches and capabilities in synthetic chemistry, chemical genetics,
informatics, and biological screening.
INVESTORS: Amgen
1/8/2004 12:14:10 PM
32. Novacea
Raises $35,000,000 in Series C Round [South San Francisco, CA]
Novacea is a biopharmaceutical company committed to creating a
drug development and commercialization organization that addresses
significant unmet medical needs. The company's first product to
enter the clinic is DN-101 (calcitriol). With DN-101, the ...
INVESTORS: Apax Partners (Lead), Domain Associates, New
Enterprise Associates (NEA), ProQuest Investments, Sofinnova Ventures,
Versant Ventures
1/8/2004 10:28:53 AM
33. PTC
Therapeutics Raises $35,000,000 in Series E Round [South Plainfield,
NJ]
PTC Therapeutics is a developer of small molecule drugs by applying
its expertise in RNA biology to modulate gene expression. The
company's pipeline includes programs in genetic disorders, oncology,
and infectious diseases.
INVESTORS: Bay City Capital, CSFB Private Equity, Delphi
Ventures, HBM Partners (HBM BioVentures), Healthcap Venture Capital,
Novartis Venture Fund, Novo, Others, POSCO BioVentures, Vulcan
Ventures
1/7/2004 11:54:45 AM
34. Protez
Pharmaceuticals Raises $800,000 in Series A Round [Malvern, PA]
Protez Pharmaceuticals is a developer of novel antibiotics for
difficult to treat infections, focusing on narrow-spectrum i.v.
and oral small molecule antibiotics for the hospital-based market.
INVESTORS: BTG
2/24/2004 2:23:07 PM
35. Graffinity
Pharmaceuticals Raises $19,000,000 in Series C Round [Germany]
Graffinity Pharmaceuticals is a company for the discovery, optimization,
and early development of small molecule pharmaceuticals. The company
is working to establish high-profile development collaborations,
while building its own pipeline of product ca...
INVESTORS: Merlin Biosciences (Lead), 3i Group, Carnegie
Bank, Dow Chemical Company, GIMV, Heidelberg Innovation, Oxford
Bioscience Partners, Technostart
2/20/2004 10:04:57 AM
36. Acuity
Pharmaceuticals Raises $2,400,000 in First Round [Philadelphia,
PA]
Acuity Pharmaceuticals uses small interfering RNA (siRNA) compounds
and technology licensed from the University of Pennsylvania to
treat vision loss caused from age-related macular degeneration
and diabetic retinopathy.
INVESTORS: Ben Franklin Technology Partners, BioAdvance
2/10/2004 10:08:21 AM
37. Saegis
Pharmaceuticals Raises $2,000,000 in Series B Round Add-on [Half
Moon Bay, CA]
Saegis Pharmaceuticals is a pioneer in the development of medicines
that protect and enhance the function of the human mind.
INVESTORS: Stanley Medical Research Institute (Lead)
1/28/2004 10:45:35 AM
38. Oculus
Innovative Sciences Raises $6,000,000 in Series A Round [Petaluma,
CA]
Oculus Innovative Sciences is a developer of technologies for
disinfectants and antiseptics. The company has developed the Microcyn
disinfectant and antiseptic that has broad applications in such
diverse markets as consumer, medical, dental, veterinari...
INVESTORS: Brookstreet Securities (Lead)
1/23/2004 10:12:42 AM
39. AmpliMed
Raises $1,700,000 in Series A Round Add-on [Tucson, AZ]
AmpliMed is a pharmaceutical company focused on the clinical development
of chemotherapeutic agents for cancer. The company’s strategy
is to develop anti-cancer drugs with novel mechanisms of action
designed to overcome some of the limitations, such as...
INVESTORS: Biotech Insight Management, InvestBio Ventures
1/22/2004 11:30:44 AM
40. DrugAbuse
Sciences Raises $4,900,000 in Bridge Financing Round [Hayward,
CA]
DrugAbuse Sciences is a developer of medications for the treatment
of alcohol and substance abuse and dependence. The company is
developing a comprehensive portfolio of products and services
dedicated to addiction medicine.
INVESTORS: CDC Ixis Private Equity
1/19/2004 2:28:26 PM
41. Speedel
Group Raises $58,000,000 in Mezzanine Round [Switzerland]
Speedel Group is a pharmaceutical company focusing on the rapid,
cost-efficient development of innovative drugs for cardiovascular
and metabolic diseases. The company has concluded licensing agreements
on four innovative compounds and on three pre-clin...
INVESTORS: Undisclosed
1/9/2004 11:36:37 AM
